Since its inception, Jefferson’s Bone Marrow Transplant Program (BMT) has completed more than 1,000 bone marrow transplants, with increasingly impressive outcomes. These include the region’s highest actual one-year patient survival rates, according to National Marrow Donor Program Center Specific analyses for 2013 and 2014. The transplant program now has an international reputation for its unique approach to haplo-identical transplants. Drs. Flomenberg, Grosso, Carabasi, Wagner, and Filicko-O’Hara all play important roles in the transplant effort. 

In an October 2014 article published in the Biology of Blood and Marrow Transplantation, Jefferson reported “disease-free and overall survival at 2 years are 74% and 77%, respectively, consistent with the findings (of previous work) and supporting the use of this approach in earlier stage patients lacking a matched related donor.”

In the BBMT’s editorial commentary, Dr. Andrea Veraldi provided praise to the Jefferson’s report, noting:

"These outcomes are extremely encouraging… All the recent reports of unmanipulated haploidentical transplantation have fostered interest and debate in the field and, most importantly, served to substantially extend its use. The new 2-step approach, as adopted by (Jefferson’s BMT Program), provides very interesting results. It is to be hoped they will be confirmed in a longer follow-up and a larger cohort of patients."

The BMT program will to conduct clinical research on the potential benefit of the two-step haplo-identical transplant approach.